Adage Capital Partners’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-66,500
| Closed | -$17.7M | – | 1065 |
|
|
2026
Q2 | $17.7M | Buy |
+66,500
| New | +$15.5M | 0.02% | 551 |
|
|
2025
Q3 | – | Sell |
-459,606
| Closed | -$79.3M | – | 886 |
|
|
2025
Q2 | $79.3M | Buy |
459,606
+132,201
| +40% | +$21.5M | 0.13% | 152 |
|
|
2025
Q1 | $51M | Buy |
+327,405
| New | +$46.8M | 0.09% | 222 |
|
|
2024
Q4 | – | Sell |
-486,957
| Closed | -$72.7M | – | 878 |
|
|
2024
Q3 | $72.7M | Sell |
486,957
-333,555
| -41% | -$45M | 0.13% | 165 |
|
|
2024
Q2 | $112M | Buy |
820,512
+611,000
| +292% | +$83.1M | 0.21% | 94 |
|
|
2024
Q1 | $31.7M | Buy |
209,512
+65,512
| +45% | +$9.35M | 0.06% | 339 |
|
|
2023
Q4 | $18.1M | Sell |
144,000
-382,371
| -73% | -$38.1M | 0.04% | 450 |
|
|
2023
Q3 | $49.3M | Sell |
526,371
-162,629
| -24% | -$15.2M | 0.11% | 200 |
|
|
2023
Q2 | $61.5M | Buy |
689,000
+189,000
| +38% | +$16.4M | 0.13% | 169 |
|
|
2023
Q1 | $53.6M | Sell |
500,000
-140,000
| -22% | -$16M | 0.12% | 201 |
|
|
2022
Q4 | $78.2M | Buy |
640,000
+410,000
| +178% | +$47.6M | 0.19% | 131 |
|
|
2022
Q3 | $23.8M | Buy |
230,000
+65,000
| +39% | +$6.16M | 0.06% | 359 |
|
|
2022
Q2 | $15.3M | Sell |
165,000
-7,000
| -4% | -$660K | 0.04% | 536 |
|
|
2022
Q1 | $20.2M | Buy |
172,000
+122,000
| +244% | +$14.1M | 0.04% | 447 |
|
|
2021
Q4 | $6.73M | Buy |
+50,000
| New | +$7.44M | 0.01% | 784 |
|
|
2020
Q3 | – | Sell |
-30,000
| Closed | -$4.44M | – | 756 |
|
|
2020
Q2 | $4.44M | Sell |
30,000
-10,000
| -25% | -$1.37M | 0.01% | 637 |
|
|
2020
Q1 | $4.5M | Hold |
40,000
| – | – | 0.01% | 584 |
|
|
2019
Q4 | $5.56M | Sell |
40,000
-160,000
| -80% | -$17.8M | 0.01% | 600 |
|
|
2019
Q3 | $19.3M | Sell |
200,000
-50,000
| -20% | -$5.58M | 0.05% | 376 |
|
|
2019
Q2 | $28.8M | Buy |
250,000
+25,000
| +11% | +$2.99M | 0.07% | 300 |
|
|
2019
Q1 | $26.5M | Sell |
225,000
-100,000
| -31% | -$8.76M | 0.07% | 318 |
|
|
2018
Q4 | $20.4M | Buy |
325,000
+75,000
| +30% | +$4.71M | 0.06% | 321 |
|
|
2018
Q3 | $17.7M | Buy |
250,000
+25,000
| +11% | +$1.72M | 0.04% | 428 |
|
|
2018
Q2 | $15M | Sell |
225,000
-350,000
| -61% | -$23M | 0.03% | 474 |
|
|
2018
Q1 | $37.6M | Buy |
575,000
+556,000
| +2,926% | +$31.2M | 0.09% | 274 |
|
|
2017
Q4 | $761K | Buy |
+19,000
| New | +$691K | ﹤0.01% | 684 |
|
Other funds holding ASND
Adage Capital Partners's ASND Position: Q3 2026 in Review
Adage Capital Partners sold out of Ascendis Pharma (ASND) in Q3 2026, closing a stake of 66,500 shares — an estimated $17.7M sold.
Adage Capital Partners first reported a position in ASND in Q4 2017 and held it in 26 quarters. The position peaked at $112M in Q2 2024. 346 funds tracked by Wall St. Rank hold ASND as of Q3 2026.
- Adage Capital Partners reported no remaining Ascendis Pharma position as of Q3 2026 after selling out during the quarter.
- Adage Capital Partners sold 66,500 Ascendis Pharma shares in Q3 2026, an estimated $17.7M.
- Adage Capital Partners first reported a position in Ascendis Pharma in Q4 2017 and held it in 26 quarters.
- Adage Capital Partners's Ascendis Pharma position peaked at $112M in Q2 2024.
- 346 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.